Literature DB >> 10370902

Pathogenesis and preclinical course of Parkinson's disease.

P Foley1, P Riederer.   

Abstract

Idiopathic parkinsonism (IP) is defined by its classic symptomology, its responsiveness to therapies which elevate dopamine levels, and by the failure to identify a specific etiological factor. The progressive and irreversible degeneration of dopaminergic neurons projecting from the substantia nigra pars compacta (SNc) to the striatum and the presence of SNc Lewy bodies are regarded as the essential pathological bases of IP, but neither the initiator(s) nor the nature of the degeneration have been determined, nor its relationship with degenerative changes in other parts of the IP brain. This paper discusses the various hypotheses that have been proposed to explain these phenomena, arguing that IP be regarded as a multisystem disorder, both at the level of individual neurons and at the whole brain level. It is probable that IP is the result of a multifactorial process, and that a cascade of interacting and overlapping biochemical mechanisms determine the course of the disease.

Entities:  

Mesh:

Year:  1999        PMID: 10370902     DOI: 10.1007/978-3-7091-6360-3_2

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  7 in total

1.  Changes in brain functional activation during resting and locomotor states after unilateral nigrostriatal damage in rats.

Authors:  J Yang; T R Sadler; T K Givrad; J-M I Maarek; D P Holschneider
Journal:  Neuroimage       Date:  2007-03-23       Impact factor: 6.556

Review 2.  Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines.

Authors:  Toshi Nagatsu; Makoto Sawada
Journal:  Cell Mol Neurobiol       Date:  2006-07-06       Impact factor: 5.046

3.  Tongue force and timing deficits in a rat model of Parkinson disease.

Authors:  Michelle R Ciucci; John A Russell; Allison J Schaser; Emerald J Doll; Lisa M Vinney; Nadine P Connor
Journal:  Behav Brain Res       Date:  2011-04-01       Impact factor: 3.332

Review 4.  α-Synuclein in Parkinson's disease: causal or bystander?

Authors:  Peter Riederer; Daniela Berg; Nicolas Casadei; Fubo Cheng; Joseph Classen; Christian Dresel; Wolfgang Jost; Rejko Krüger; Thomas Müller; Heinz Reichmann; Olaf Rieß; Alexander Storch; Sabrina Strobel; Thilo van Eimeren; Hans-Ullrich Völker; Jürgen Winkler; Konstanze F Winklhofer; Ullrich Wüllner; Friederike Zunke; Camelia-Maria Monoranu
Journal:  J Neural Transm (Vienna)       Date:  2019-06-25       Impact factor: 3.575

5.  Imaging changes associated with cognitive abnormalities in Parkinson's disease.

Authors:  Yuko Koshimori; Barbara Segura; Leigh Christopher; Nancy Lobaugh; Sarah Duff-Canning; Romina Mizrahi; Clement Hamani; Anthony E Lang; Kelly Aminian; Sylvain Houle; Antonio P Strafella
Journal:  Brain Struct Funct       Date:  2014-05-13       Impact factor: 3.270

Review 6.  The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start?

Authors:  Junghee Lee; Jung Hyun Boo; Hoon Ryu
Journal:  Adv Drug Deliv Rev       Date:  2009-08-27       Impact factor: 15.470

Review 7.  Parkinson's disease: a dual-hit hypothesis.

Authors:  C H Hawkes; K Del Tredici; H Braak
Journal:  Neuropathol Appl Neurobiol       Date:  2007-10-24       Impact factor: 8.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.